Berlin, Germany and Konstanz, Germany, August 19, 2005. PSF
biotech announced today that they have extended their pre-existing
research collaboration in the field of structure-based drug design with
ALTANA Pharma AG. PSF expresses ALTANA Pharma’s target proteins
and co-crystallizes them with ALTANA Pharma’s own ligands. The
structural elucidation of these proteins in complex with ligands allows
for rapid optimization of active substances by computational
approaches and for design of new and innovative drugs. Financial
terms of the agreement were not disclosed.
Commenting on the collaboration Dr. Dominik, Senior Director
Enabling Technologies of ALTANA Pharma said, "In today’s
pharmaceutical research three-dimensional structures of our
molecular targets are an essential tool for efficient and targetoriented
drug discovery and optimization. I am very pleased to be
collaborating with the team of highly motivated scientists at PSF
biotech, who are contributing to our in-house projects and providing
us with us with cutting-edge technology".
"We are pleased to extend this already successful collaboration, in
which we are now working with a relevant fraction of ALTANA
Pharma’s protein targets across various indication fields," added
Dr. Gerd Illing, Chief Executive Officer of PSF biotech. "Our highthroughput
structural biology platform fits perfectly well to ALTANA
Pharma’s needs for successive protein structural information."
About PSF biotech AG (www.psf-ag.com)
PSF biotech (the protein structure factory®) combines state-of-the-art
expertise and resources for structure-based drug design. The
company is located in Berlin and was founded in 2000. Based on its
high-throughput synchrotron crystallography and NMR platform, PSF
offers comprehensive services for lead optimization, structural target
validation and characterization of protein drugs. In addition, PSF
produces active, properly folded proteins, optionally labeled for NMR
and crystallography. PSF is absolutely committed to their customers'
needs, shortening the time to market substantially, saving costs per
drug and reducing the rate of failure.
Contact for further information:
PSF biotech AG
Dr. Gerd Illing
Phone: +49(0) 30 32639 271